Drug intelligence / Profile preview

travoprost + timolol + brinzolamide + brimonidine

Development stage: Unknown
Lead developer: Novartis
Modality: Small Molecules
Administration: Ophthalmic

Overview

A combination of four medications used as maximal medical therapy (MMT) for glaucoma and ocular hypertension. This approach involves using two separate fixed-dose combinations together: travoprost 0.004%/timolol 0.5% (TTFC) and brinzolamide 1%/brimonidine 0.2% (BBFC). The combination provides significant intraocular pressure (IOP) reduction through multiple mechanisms of action.

Targets

ADRB1 (β1)ADRA2A (α2A)PTGFR (Prostaglandin F2 alpha receptor)CA2 (Carbonic Anhydrase 2)

Beyond the preview

Go deeper on travoprost + timolol + brinzolamide + brimonidine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on travoprost + timolol + brinzolamide + brimonidine.

Explore the full profile